Balyasny Asset Management
ORTX

Balyasny Asset Management’s Orchard Therapeutics plc American Depositary Shares ORTX Stock Holding History

Balyasny Asset Management’s Portfolio ORTX Stock Details ORTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-3,372
Closed -$17K – 3353
2022
Q3 		$17K Buy
+3,372
New +$18.8K ﹤0.01% 2600
2019
Q3 		– Sell
-22,909
Closed -$3.21M – 1699
2019
Q2 		$3.21M Buy
+22,909
New +$4.02M 0.02% 740

Other funds holding ORTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
CA
CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Balyasny Asset Management's ORTX Position: Q4 2022 in Review

Balyasny Asset Management sold out of Orchard Therapeutics plc American Depositary Shares (ORTX) in Q4 2022, closing a stake of 3,372 shares — an estimated $17K sold.

Balyasny Asset Management first reported a position in ORTX in Q2 2019 and held it in 2 quarters. The position peaked at $3.21M in Q2 2019. 47 funds tracked by Wall St. Rank hold ORTX as of Q4 2022.

  • Balyasny Asset Management reported no remaining Orchard Therapeutics plc American Depositary Shares position as of Q4 2022 after selling out during the quarter.
  • Balyasny Asset Management sold 3,372 Orchard Therapeutics plc American Depositary Shares shares in Q4 2022, an estimated $17K.
  • Balyasny Asset Management first reported a position in Orchard Therapeutics plc American Depositary Shares in Q2 2019 and held it in 2 quarters.
  • Balyasny Asset Management's Orchard Therapeutics plc American Depositary Shares position peaked at $3.21M in Q2 2019.
  • 47 funds tracked by Wall St. Rank held Orchard Therapeutics plc American Depositary Shares as of Q4 2022.

Based on Balyasny Asset Management's 13F filing for Q4 2022, filed 14 Feb 2023.